CANY
ARRY

Caxton Associates (New York)’s Array Biopharma Inc ARRY Stock Holding History

Caxton Associates (New York)’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15,900
Closed -$142K – 604
2017
Q1 		$142K Buy
+15,900
New +$169K ﹤0.01% 372

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Caxton Associates (New York)'s ARRY Position: Q2 2017 in Review

Caxton Associates (New York) sold out of Array Biopharma Inc (ARRY) in Q2 2017, closing a stake of 15,900 shares — an estimated $142K sold.

Caxton Associates (New York) first reported a position in ARRY in Q1 2017 and held it in 1 quarter. The position peaked at $142K in Q1 2017. 182 funds tracked by Wall St. Rank hold ARRY as of Q2 2017.

  • Caxton Associates (New York) reported no remaining Array Biopharma Inc position as of Q2 2017 after selling out during the quarter.
  • Caxton Associates (New York) sold 15,900 Array Biopharma Inc shares in Q2 2017, an estimated $142K.
  • Caxton Associates (New York) first reported a position in Array Biopharma Inc in Q1 2017 and held it in 1 quarter.
  • Caxton Associates (New York)'s Array Biopharma Inc position peaked at $142K in Q1 2017.
  • 182 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2017.

Based on Caxton Associates (New York)'s 13F filing for Q2 2017, filed 14 Aug 2017.